Vaxart Inc Stock Price, News & Analysis

Vaxart, Inc. (NASDAQ: VXRT) announced the appointment of Karen J. Wilson to its Board of Directors and as chair of the Audit Committee. With over 30 years in finance within the life sciences sector, Wilson's experience is expected to bolster Vaxart's growth as they advance their oral COVID-19 vaccine candidate. CEO Andrei Floroiu highlighted her expertise as a significant asset for the company, which is focused on developing oral vaccines for various infectious diseases. Vaxart’s innovative tablet vaccines aim to simplify distribution and enhance pandemic response.

Vaxart, Inc. (NASDAQ: VXRT) recently announced a study in the Journal of Infectious Diseases highlighting that norovirus gastroenteritis costs the U.S. approximately $10.6 billion annually, primarily due to sporadic cases rather than publicized outbreaks. Conducted by PHICOR, the study suggests over 50% of these costs occur during winter months, emphasizing the need for timely preventative measures. Furthermore, productivity losses account for 89% of overall costs, underscoring the substantial economic burden. Vaxart supports the research to advance its oral norovirus vaccine program.

Vaxart, Inc. (NASDAQ: VXRT) announced it raised approximately $90 million through its At-the-Market facility, selling 11.2 million shares at $7.98 each. The funds will support clinical development and product manufacturing. SVB Leerink and B. Riley FBR are involved as sales agents. The offering was made under an effective shelf registration statement filed with the SEC. Vaxart focuses on developing oral vaccines for infectious diseases, including COVID-19, with the goal of achieving easier distribution compared to injectable vaccines.

Vaxart, a clinical-stage biotechnology company, has signed a Memorandum of Understanding with AMS for the large-scale production of its oral COVID-19 vaccine. This partnership aims to enable the manufacture of over a billion doses annually, facilitating distribution in the US, Europe, and other regions. CEO Andrei Floroiu highlighted the logistical advantages of Vaxart's room-temperature stable tablet vaccine, which may provide enhanced protection against airborne viruses. The company continues to focus on developing oral vaccines for various infectious diseases.

Vaxart, a clinical-stage biotech firm, announced its inclusion in the Russell 3000 Index effective June 29, 2020. This membership enhances the company's visibility among institutional investors and could increase stock liquidity. Vaxart is focused on developing oral vaccines for various infectious diseases, including COVID-19. The Russell 3000 is a benchmark for approximately $9 trillion in assets, which could further drive Vaxart's growth. CEO Andrei Floroiu expressed optimism about the company's innovative oral vaccine approach and its potential advantages over traditional injectables.

Vaxart, Inc. (NasdaqCM: VXRT) has appointed Andrei Floroiu as the new Chief Executive Officer. With extensive experience in the biopharma sector, particularly in vaccine and business development, Floroiu aims to drive the company's growth, especially in light of COVID-19 vaccine development. He previously held executive roles at Agenus, where he structured significant partnerships. Vaxart currently holds approximately $30 million in cash, which supports its innovation in oral recombinant vaccine technology, designed for various infectious diseases.

SOUTH SAN FRANCISCO, Calif., June 3, 2020 - Vaxart (NASDAQ: VXRT), a clinical-stage biotechnology company, announced that CEO Wouter Latour will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 2:00 p.m. Eastern Time. This event will feature presentations and panels from over 400 healthcare companies and 2,500 executives and investors, discussing investment opportunities and healthcare trends. Vaxart specializes in developing oral recombinant vaccines, aiming to improve vaccination rates and protection against infectious diseases with its tablet-based delivery system.

Vaxart, a clinical-stage biotechnology company, has contracted with KindredBio to manufacture its lead COVID-19 vaccine candidate under cGMP standards. This decision complements existing manufacturing capabilities with Emergent BioSolutions. The vaccine, based on Vaxart's oral tablet platform, aims to generate strong immune responses and is expected to enter Phase 1 clinical trials in the second half of 2020. Vaxart's platform offers a more convenient vaccine delivery method compared to traditional injections, potentially increasing vaccination rates.

Vaxart announced promising preclinical results for its oral COVID-19 vaccine candidates, which demonstrated robust antibody responses in tested animals. The company plans to initiate a Phase 1 clinical study in the second half of 2020. Financially, Vaxart reported a net loss of $1.3 million for Q1 2020, identical to Q1 2019, but with a reduced net loss per share of $0.02 compared to $0.18 in the prior year. Cash equivalents increased to $29.9 million due to a successful stock offering, despite a revenue decline to $2.9 million from $5.4 million in Q1 2019.